Incidence Of Malignancy Research Articles

Incidence of cancer after paediatric solid organ transplant recipients: A Scoping Review

Background: To investigate the incidence of post-transplant malignancies in paediatric recipients of solid organ transplants. Materials and Methods: We searched MEDLINE, Scopus and Web of Science up to January 2025 for observational studies reporting on cancer incidence in children who underwent solid organ transplantation (SOT). Data extraction and quality assessment were performed by two independent reviewers. Data on incidence rates, types of malignancies, and patient demographics were extracted and analysed. Results: Sixteen studies with a total of 26,310 paediatric transplant recipients were included. The cumulative incidence of cancer after kidney transplantation ranged from 10.2% at 15 years to 27% at 25 years. For liver transplantation, the incidence was 22% at 25 years, with a range from 3.4% to 7.1% incidence of post-transplant lymphoproliferative disorders (PTLD). Following heart transplantation, the incidence was 30.5% at 10 years. Conclusions: Paediatric solid organ transplant recipients face a significant risk of developing cancer, particularly PTLD. Regular monitoring and early intervention are essential for improving long-term outcomes.

Spondyloarthritis and Risk of Malignancy: A Narrative Review on a Still Controversial Issue.

Current literature regarding cancer risk in rheumatic and musculoskeletal diseases (RMDs) is particularly poor and controversial, even though the incidence of malignancy in some patients with RMDs is considered to be increased compared with the general population. Malignancy may be a major comorbidity in subjects with spondyloarthritis (SpA) as the result of multifactorial mechanisms, from disease pathogenesis to the iatrogenic effect of immunomodulating drugs. Several recommendations for screening and management of cancer risk have been developed in recent years with the aim of improving the different outcomes in these patients. The goal of this narrative review is to provide an overview of the currently available evidence on the risk of malignancy connected with RMDs and examine the association of SpA with cancer and the potential impact of its treatment with biologic and targeted synthetic disease-modifying anti-rheumatic drugs on development of malignancy.

Associations Between Immune-Related Conditions and Lymphoid Disorders: An Analysis of the Diverse All of Us Research Program

Introduction: Studies on the association between immune-mediated disorders and lymphoid disorders have been very limited, especially in diverse populations. The objective of this study is to evaluate the relationship between a variety of immune diseases and lymphoid malignancies. Methods: The NIH “All of Us” database was utilized to perform a cross-sectional analysis between lymphoid disorders and various immune diseases. The adjusted multivariable logistic regression analysis was performed in R to examine the association between lymphoid disorders such as leukemia, lymphoma, and plasma cell neoplasms against a variety of autoimmune diseases. Results: In the study cohort of 316,044 patients, we found significant associations between lymphomas and the aforementioned immune-mediated diseases, with the exception of dermatomyositis and scleroderma. Lymphoid leukemias showed significant associations (p < 0.001) with several autoimmune conditions, including psoriasis, type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, and hyperthyroidism. In plasma cell neoplasms, significant associations were found in all but dermatomyositis, scleroderma, vitiligo, and atopic dermatitis (p < 0.001). Conclusions: In this population-level analysis, the majority of immune-mediated diseases were found to be significantly correlated with an increased incidence of lymphoid malignancies. As such, patients diagnosed with immune-mediated diseases should undergo close surveillance and early screening with the goal of early identification and treatment of lymphoid malignancies.

Usage of Milan System in Risk Stratification of Submandibular Gland Fine Needle Aspiration Cytology.

The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) categorizes fine needle aspiration and cytology (FNAC) results into 6 tiers and assigns a risk of malignancy (ROM) to each category. Its utility in submandibular gland lesions remains unclear. Our article aims to study (1) the utility of the MSRSGC in classifying FNAC of submandibular gland masses, (2) describe the demographics and incidence of submandibular gland malignancy in our population, and (3) analyze the accuracy of FNAC in diagnosis of benign and malignant submandibular gland tumors. In this retrospective case series, the FNAC results of 92 patients who underwent pre-operative FNAC and excision of submandibular gland between May 2008 and December 2023 were reviewed and assigned to a MSRSGC category, and ROM was calculated based on histological diagnosis. 20/92 (21.7%) submandibular gland excisions with pre-operative FNAC were malignant. ROM is as follows: non-diagnostic 7.1%, non-neoplastic 12.5%, atypia of undetermined significance 35.3%, benign neoplasm 3.3%, salivary gland neoplasm of uncertain malignant potential 35%, suspicious for malignancy 100%, and malignant 100%. Our study validates the usage of the MSRSGC in the work up of submandibular gland tumors. 4 Laryngoscope, 2025.

P1228 Cancer incidence in patients with inflammatory bowel disease: A nationwide population-based study from Korea

Abstract Background Inflammatory bowel disease (IBD) is a chronic condition associated with systemic inflammation and potential long-term complications, including an elevated risk of malignancy. While colorectal cancer has been a well-documented concern, data on overall cancer risks in patients with IBD remain limited, particularly in Asian populations. This study aimed to evaluate the incidence of malignancy in Korean patients with IBD compared to the general population. Methods We analysed data from the Korean National Insurance claims database between 2007 and 2022. Cancer occurrence in the general population during the corresponding years was sourced from the National Cancer Registry. Standardized incidence ratios (SIRs), adjusted for age and sex, for each year from 2010 to 2021 were calculated for overall malignancy in patients with IBD and compared with the general population. For visual representation, the SIR values and their 95% confidence intervals were plotted using cubic spline interpolation to create a continuous visualization of annual trends. Results A total of 66,392 patients with IBD were analysed, including 20,503 with Crohn’s disease (CD) and 45,889 with ulcerative colitis (UC). The median follow-up time from IBD diagnosis was 6.6 years (interquartile range, 3.5–10.5) (Table 1). During follow-up, a total of 2,895 malignancy cases occurred in the IBD group. Compared to the expected malignancy cases of 1,837 of the age- and sex-standardized general population, the SIR was significantly increased at 1.576 (95% CI (confidence interval), 1.519–1.634). Further stratification by time periods revealed distinct temporal trends in malignancy risk. During 2010–2015, the SIR was 1.037 (95% CI, 0.950–1.133), reflecting an incidence rate similar to the general population. In contrast, during 2016–2021, the SIR increased significantly to 1.765 (95% CI, 1.696–1.837), indicating a marked rise in the incidence of overall malignancy among patients with IBD in their later follow-up years (Figure 1). Conclusion Korean patients with IBD have a significantly elevated malignancy risk compared to the general population, particularly during their later follow-up years. This highlights the importance of continued cancer surveillance and preventive strategies in this population.

Sodium-glucose cotransporter 2 inhibitor treatment has differential effects on the incidence of various malignancies: Evidence from a spontaneous adverse reaction database.

Sodium-glucose cotransporter (SGLT) 2 inhibitors are expected to demonstrate secondary effects against malignancy. However, long-term and large-scale data are required to evaluate the effects of SGLT2 inhibitors on malignancy, which has not been sufficiently studied in clinical practice. This study aimed to evaluate the association between SGLT2 inhibitors and malignancy using the spontaneous adverse reaction database. The United States Food and Drug Administration Adverse Event Reporting System database between 1997 (4Q) and 2020 (2Q) was used in this study. Reporting odds ratio (ROR) was selected as the safety-signaling measure. An inverse signal suggesting potential alternative therapeutic opportunities was defined when the upper limit of 95% confidence interval (CI) was < 1. The association between SGLT2 inhibitors and malignancies was evaluated. The total number of reports in the database during the study period was 13,106,455. SGLT2 inhibitors showed significant associations with pancreatic cancer (ROR: 3.08. 95% CI: 2.68 - 3.55), and kidney cancer (ROR: 1.39. 95% CI: 1.13 - 1.72). SGLT2 inhibitors showed significant inverse associations with breast cancer (ROR: 0.32. 95% CI: 0.27 - 0.39), lung cancer (ROR: 0.47. 95% CI: 0.37 - 0.59), liver cancer (ROR: 0.68. 95% CI: 0.50 - 0.93), and malignant melanoma (ROR: 0.49. 95% CI: 0.34 - 0.70). SGLT2 inhibitors may increase the incidence of pancreatic cancer and kidney cancer, and decrease the incidence of breast cancer, lung cancer, liver cancer, and malignant melanoma. These associations need to be further examined in other clinical studies and research in the future.

The Incidence of Malignant and High-Risk Pathology Findings in Postreduction Mammaplasty Patients.

Introduction: Reduction mammaplasty is often performed to alleviate symptoms of macromastia or for symmetry after a lumpectomy in the contra-lateral breast. Abnormal pathology including breast cancer can be incidentally found in reduction mammaplasty specimens, but there is no consensus on risk factors or detection rates. This study aimed to elucidate the incidence of malignant and high-risk pathology findings in patients undergoing breast reduction in a Canadian context. Methods: We conducted a retrospective review of all reduction mammaplasty cases performed by 5 surgeons between January 2001 and May 2023. Patients were categorized into Group A, those undergoing bilateral reduction for macromastia symptoms, and Group B, those with a history of breast-conserving surgery seeking unilateral reduction postlumpectomy. Results: In total, 1383 breasts from 872 patients were examined: 1022 in Group A and 361 in Group B. Group B was significantly older (56.9 ± 9.3 vs 44.0 ± 13.9 years) whereas Group A had a significantly higher BMI (33.1 ± 8.4 vs 30.1 ± 5.8). High-risk and malignant pathology incidence was 1.4% overall. The sole malignancy detected was in a patient in Group A without prior breast cancer history. Multivariate analysis revealed BMI as a significant predictor for high-risk pathologies (OR 1.134, 95% CI [1.012-1.271]). Conclusions: Our findings align with previously reported incidence rates of pathological findings in mammaplasty specimens and highlight the correlation between BMI and pathology risk. These results underscore the importance of a comprehensive history and preoperative counselling about the possibility of further treatment following pathological discoveries during reduction mammaplasty.

Comparison of the effectiveness of RB and R-CHOP regimens in first-line therapy in 277 patients with grade 1–2 follicular lymphoma: a retrospective single-center analysis

Background. Chemoimmunotherapy, including cytotoxic drugs and anti-CD20 monoclonal antibodies have significantly improved outcomes in patients with newly diagnosed follicular lymphoma (FL) compared with chemotherapy. A number of clinical studies have compared the effectiveness of the two most popular treatment regimens, rituximab plus bendamustine (RB) and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP), with conflicting results.Aim. To conduct a retrospective analysis of the treatment results of a large cohort of patients with grade 1–2 FL who received RB or R-CHOP regimens in the first line therapy in real-life clinical practice, to analyze the impact of individual prognostic factors, as well as rituximab maintenance therapy on survival, the incidence of secondary malignancies and causes of mortality.Materials and methods. Data were collected on patients with grade 1–2 FL who were treated at the Botkin Hospital from November 2006 to November 2022. The inclusion criteria for the study were newly diagnosed histologically confirmed FL of grade 1–2, age ≥18 years, RB or R-CHOP therapy as first line. No radiation therapy was allowed. Response assessment was performed according to the 2007 International Working Group criteria.Results. The inclusion criteria for the study were met by 277 patients; 164 patients received R-CHOP and 113 patients received RB. Overall response rate was comparable between groups (96 % vs 94 % in the RB and R-CHOP groups, respectively, p = 0.3396). The median followup period was 35 (3–117) months in the RB group and 50 (3–200) months in R-CHOP group. The median progression-free survival (PFS) in the R-CHOP group was 86 months, while the median of PFS in the RB group was not reached, the differences did not reach statistical significance (hazard ratio (HR) 0.65; 95 % confidential interval (CI) 0.42–1.004; p = 0.0665). Three-year PFS was 81 and 72 %, and five-year PFS was 66 and 57 % in the RB and R-CHOP groups, respectively. Progression within 24 months of initiation of therapy was more common in R-CHOP group (20 % vs 11 %, p = 0.0466). The median time to next therapy in R-CHOP group was 90 months and was not reached in RB group (HR 0.75; 95 % CI 0.48–1.18; p = 0.2277). Unifactor analysis of individual prognostic factors showed superior PFS in most subgroups receiving RB regimen. R-CHOP regimen showed a trend towards improved PFS only in patients with maximum standardized uptake value (SUVmax) &gt;14 (HR 2.46; 95 % CI 0.52–11.62; p = 0.2211). The use of rituximab maintenance therapy improved PFS in both treatment groups: in R-CHOP group, the differences reached the level of significance (HR 0.22; 95 % CI 0.05–1.01; p&lt;0.0001) , in RB group they did not reach the level of significance (HR 0.41; 95 % CI 0.02–8.67; p = 0.3605). There were no significant differences in overall survival. The 5-year cumulative incidence of secondary malignancies as well as the incidence of grade 5 infections were comparable between groups.Conclusion. In summary, our study shows that RB regimen generally has comparable long-term efficacy to R-CHOP regimen in first-line therapy in patients with grade 1–2 FL. Unifactor analysis of individual prognostic factors showed better PFS in most subgroups using the RB regimen. The use of rituximab maintenance therapy significantly improved PFS in R-CHOP group compared with RB regimen. Our study with a significant median follow-up did not find differences in the incidence of secondary malignancies or non-lymphoma related mortality.

Role of neck dissections in the management of carotid body tumors.

Carotid body tumors (CBTs) are rare neoplasms of the paraganglia at the carotid bifurcation. While typically benign, CBTs occasionally exhibit malignancy, metastasizing to nearby lymph nodes. Histopathologic analysis alone is insufficient to confirm malignancy, requiring metastases to non-neuroendocrine tissue for a definitive diagnosis. The role of selective neck dissections (SNDs) in detecting malignancy and guiding subsequent management remains uncertain. A retrospective case series through electronic chart review was performed on 21 patients undergoing CBT surgeries between 2002 and 2022 at a Canadian institution. SNDs were performed on all 21 patients. Data collection included patient demographics, genetic and laboratory testing results, preoperative imaging, intraoperative and postoperative complications, histologic analysis of neck SND and tumor specimen, and follow-up results. Of the 21 surgical resections, there were three cases (14.3%) of carotid artery injuries and six cases (28.6%) of nerve injuries. One patient (4.8%) experienced three intraoperative strokes. Three patients (14.3%) were found to have lymph node involvement, confirming malignancy, and underwent further treatment with radiotherapy. Interestingly, two patients with carotid injuries had malignant tumors, demonstrating a statistical significance between carotid injury and malignancy (OR 34.00, 95% CI: 1.48, 781.83, p = .041). SNDs are a useful adjunct in detecting malignancy during CBT surgeries. The incidence of malignancy in CBT is low but not negligible, and SND should be considered in patients to prevent inadvertent underdetection of metastatic disease. This study's 14.3% incidence of malignancy suggests that there may be a rationale for considering the universal implementation of SND during CBT resections. 4.

Incidence and impact of other malignancies after immunochemotherapy by fludarabine, cyclophosphamide, and rituximab as frontline treatment for chronic lymphocytic leukemia: A single-center retrospective study.

Individuals with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have a high risk of developing other malignancies (OMs). The development of OMs may be associated with the advanced age of CLL/SLL patients, presence of a tumor-promoting microenvironment, immune alterations inherent to CLL/SLL, or chemotherapy. Importantly, the occurrence of OMs following frontline fludarabine, cyclophosphamide and rituximab (FCR) treatment is associated with a reduction in the overall survival (OS). This retrospective study included 108 CLL/SLL patients treated with FCR immunochemotherapy, as a first line treatment. With a median follow-up of 94.9 (6-222) months, 31% developed an OM or more, within a median of 61.8 months post-FCR initiation. The most common OMs were non-melanoma skin cancers (7%), Richter’s syndrome (RS) (7%), myelodysplastic syndromes (6%), prostate cancer (4%), and acute myeloid leukemia (3%). Patients with OMs had shorter survival compared to those without (104.0 versus 149.0 months, P=0.02), with RS having the worst OS at 4.8 months (P&lt;0.0001), followed by therapy-related myeloid neoplasia (t-MN) at 14.5 months. Although the onset of OMs in patients with CLL/SLL was observed after considerable delays, its impact on survival is significant in the immunochemotherapy era, necessitating a better understanding of these patterns to improve CLL/SLL management and guide future treatment strategies.

Incidence, Management, and Survival of Pancreatic Malignancies in Children: A Population-based SEER Study

Incidence, Management, and Survival of Pancreatic Malignancies in Children: A Population-based SEER Study

Hepatitis C Virus Infection in Hemodialysis Patients in the Era of Direct-Acting Antiviral Treatment: Observational Study and Narrative Review.

Background and Objectives: Hepatitis C virus (HCV) infection is a major global public health concern, particularly in hemodialysis (HD) patients. This study aims to evaluate the demographic, clinical, and laboratory characteristics of HCV-positive patients undergoing HD and assess the long-term impact of direct-acting antivirals (DAAs) on patient outcomes. Moreover, a narrative review aims to summarize the current knowledge regarding HCV treatment in HD patients. The search in the PubMed, Google Scholar, and Scopus databases identified 48 studies relevant to our topic, 18 regarding clinical history and 29 related to HCV treatment. Methods: A retrospective analysis was performed on 165 HD patients from Bihor County HD centers, Romania, between 2014 and 2024. The cohort was divided into two groups: 54 patients who tested positive for HCV and 111 controls who were HCV-negative. Data collected from GPs included demographic information, comorbidities, laboratory parameters, and psychological assessments. Outcomes were evaluated at over 5 years after DAA treatment. A literature review was conducted using PubMed and Google Scholar to identify relevant studies on HCV in HD patients from 1989 to 2024. Results: Laboratory results showed similar parameters across groups, except for lower serum cholesterol levels in the HCV-positive DAA-treated group vs. HCV-positive non-treated ones (155.607 mg% vs. 170.174 mg%, p = 0.040) and increased ALT levels when comparing the same groups (29.107 vs. 22.261, p = 0.027), whereas comorbidities did not differ significantly. The incidence of malignancies was significantly higher among HCV-positive compared to HCV-negative patients (20.3% vs. 8.1%, p = 0.023), mainly among those treated with DAAs, highlighted by the multivariate analysis. Cardiovascular disease remains the leading cause of mortality regardless of HCV status or the use of antiviral therapy. Psychological assessments revealed more severe depression in HCV-positive patients compared to their HCV-negative counterparts. Conclusions: HCV infection in the hemodialysis population typically follows a subclinical course. At over five years after DAA therapy, the results indicate a stabilization of the liver function and the absence of major complications. However, the incidence of malignancies remains high in HCV-positive patients.

Incidental pancreatic cystic lesions: retrospective analysis of natural history and efficacy of imaging surveillance guidelines.

To assess the natural history of incidental pancreatic cystic lesions (PCLs) and the sensitivity of surveillance guidelines to detect malignancy. We performed a single-center retrospective analysis of incidental PCLs discovered between 2012 and 2017. Patients were identified by searching radiology reports for relevant keywords, then search results were manually reviewed to exclude patients with < 5 years of follow-up, non-incidental PCLs, known pancreatic cancer, or pancreatitis. Baseline and follow-up imaging was reviewed to record size, growth (as defined by the American College of Radiology (ACR)), high-risk stigmata, and incidence of malignancy. Four major guidelines (International Consensus, European, ACR, and Canadian Association of Radiologists (CAR)) were retrospectively applied to assess sensitivity to detect invasive disease. Benign and malignant PCL outcomes were compared (Fisher's exact test), and PCL growth was modeled (mixed-effects regression). Four hundred and forty-nine patients (67 ± 12 years, 284 women) with 556 PCLs were included. PCL natural growth was 0.33 mm/year (0.26-0.40 mm 95% CI), which overlaps with significant growth thresholds for ACR and CAR guidelines. Nine patients over 21,996 patient-years of follow-up developed pancreatic cancer (4.1 cases/10,000 patient-years). Malignancy was not associated with significant growth (4/9 vs 107/547, p = 0.084) but was with high-risk stigmata (3/9 vs 3/547, p < 0.001). Guideline sensitivities ranged from 33.3 to 66.7% (2-4/6 cases). PCLs are common, overwhelmingly benign, and grow slowly. Development of high-risk stigmata is associated with malignancy but not "significant growth," which can overlap with natural PCL growth. Despite differences in recommended duration and frequency of follow-up, surveillance guidelines still miss 1/3-2/3 of cancers. Question There is limited evidence on the natural growth and malignant potential of incidental pancreatic cystic lesions. Findings Incidental pancreatic cystic lesions grew slowly (0.3 mm/year) and were uncommonly malignant (2%). Retrospective application of surveillance guidelines missed 1/3-2/3 of cancers. Clinical relevance Radiologists and imaging surveillance guidelines should account for the natural growth of incidental pancreatic cystic lesions. Given the low rate of malignancy, high proportion of missed cancers, and risk of overtreatment, the effectiveness of imaging surveillance guidelines remains unclear.

The necessity of fine-needle aspiration biopsy in surgical decision-making for thyroid nodules larger than 3 cm.

Ultrasound-guided fine-needle aspiration biopsy (FNAB) is an essential diagnostic tool for detecting malignancy in thyroid nodules. The objective of this study was to evaluate the necessity of FNAB in the treatment decision-making process for thyroid nodules exceeding 3 cm in size. The records of patients who underwent thyroidectomy in our center between 2018 and 2023 were retrospectively reviewed. The study included patients with an index nodule size exceeding 3 cm. Exclusion criteria were missing data, treatment for a different oncological condition, recurrent disease, and purely cystic nodule. Patients were categorized into 2 groups based on the size of the index nodule: Group 1 included nodules measuring between 3 to 4 cm, and Group 2 included nodules 4 cm and larger. Demographic data, FNAB results, and histopathological findings were recorded. The specificity, sensitivity, false negative, and false positive rates of FNAB were calculated. There were 1935 patients who underwent thyroidectomy within the specified date range. In 359 of these patients, the index nodule size was 3 cm or more. There were 188 patients with nodule size between 3 and 4 cm. The mean age was 50.42 ± 13.34 years, and 257 patients were female (F/M ratio = 2.5/1). Fine needle aspiration biopsy was performed on 237 patients, resulting in 65 false negatives. Both the incidence of malignancy and the rate of FNAB false negatives were higher in nodules measuring 4 cm or larger. This study identified a high malignancy rate and a significant rate of false negatives in FNAB of thyroid nodules larger than 3 cm. These findings highlight the importance of carefully considering these factors in the surgical planning of such nodules.

Updates in Human Papillomavirus Vaccination to Improve Medical Readiness in Active Duty Service Members.

Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States and is associated with the development of genital warts, precancerous lesions, and cancers of the oropharynx, anus, penis, vulva, vagina, and cervix. HPV-associated diseases are preventable through vaccination. An Australian nationwide vaccination program will effectively eliminate cervical cancer as a public health concern by the year 2035. Despite safety and efficacy data, vaccination against HPV is not mandatory for military service members. Active duty service women are more likely to test positive for HPV when compared to dependents, and veterans diagnosed with HPV-associated cancers have higher health care resource utilization and costs. Even if a patient has a prior HPV infection, vaccination at the time of HPV diagnosis or following treatment can reduce recurrence of HPV and dysplasia. In addition, patients with a history of cancer have a higher incidence of secondary HPV-associated malignancies and should be offered vaccination or re-vaccination if they received a hematopoietic stem-cell transplant. Improving HPV vaccination rates within the military health system requires a multidisciplinary approach. Providers should use every opportunity to recommend HPV vaccination, including recommending HPV vaccines for individuals who do not have a record of HPV vaccination. The electronic health record can be utilized to generate prompts for vaccine reminders, and clinics should stock HPV vaccines to allow for easy administration. Additionally, adoption of an opt-out policy for HPV vaccines rather than mandatory vaccination may be an acceptable alternative to increase HPV vaccination while allowing active duty service members to retain autonomy.

The Prevalence and Diagnostic Patterns of Oral and Maxillofacial Lesions: A Seven-Year, Retrospective, Single-Center Cone Beam Computed Tomography and Histopathology Study in Saudi Arabia.

Objective: To determine the prevalence of oral and maxillofacial lesions among patients at King Abdulaziz University from January 2016 to December 2022. Methods: This cross-sectional observational study included patients diagnosed with oral and maxillofacial intra-bony lesions based on radiological findings and confirmed by histopathological examination. The lesions were classified according to the fourth edition of the World Health Organization Classification of Head and Neck Tumors. Results: This study included 237 patients with a mean age of 31.53 ± 14.97 years, of which 45.1% were female. Most patients (46.7%) had mandibular lesions, followed by maxillary lesions (35.9%). Only 2.95% of the tumors were malignant. Odontogenic cysts were the most prevalent (65.40%), with radicular cysts and keratocytes being the most common types. The most prevalent tumor types were odontoma and ameloblastoma. The most malignant lesion was multiple myeloma. Conclusions: Our findings reveal that mandibular cystic lesions predominated, and emphasize the low incidence of malignancy in the study population. They provide valuable insights into the oral and maxillofacial lesion landscape at a high-volume tertiary care center.

Second primary cancers: Incidence and outcomes from a population of patients accrued in six prospective controlled trials at a tertiary cancer institute.

The aim of this study was to document the incidence, spectrum and outcomes of Second Primary Malignancy (SPM) in a prospectively followed-up population of Head and Neck Squamous carcinoma (HNSCC) patients accrued in six prospective trials and treated with definitive radiotherapy. Patients were prospectively followed up over time and data on SPM collected after IRB approval after establishing the diagnosis of SPM based on clinical criteria. Descriptive statistics to determine clinic demographic characteristics and spectrum of SPM encountered, time to event outcomes (SPM-DFS - Disease-free survival after diagnosis of second primary, SPM-OS - Overall survival after diagnosis of second primary) and univariate analysis of factors of likely prognostic significance were performed. A total of 656 individual patient records were examined. A total of 43 SPM s were detected at a median follow-up of 62 months (IQR -39-97 months), accounting for a cumulative incidence of 6.5%. The median time to development of an SPM was 48 months. The head and neck (41.84%) and the esophagus (34.8)% were the most common sites of SPM. At a median follow-up of 7 months post-diagnosis of SPM, the 1 year estimates of SPM-DFS and SPM-OS were 37.6% and 40% respectively. Radical intent treatment emerged as a significant predictor of improved SPM-OS and SPM-DFS. SPMs are a major cause of morbidity and mortality in HNSCC survivors. Timely detection allows for more cases to be treated with radical intent to offer chances for long term control and survival.

Cancer Incidence and Outcome for Patients With Rheumatoid Arthritis: A Long-Term Population Study in Western Australia.

Our aim was to compare the incidence of malignancy and its effect on mortality between hospitalized patients with rheumatoid arthritis (RA) and controls. We conducted a population-level observational study of patients with RA (International Classification of Diseases, 9th revision, Clinical Modification [ICD-9-CM] code 714 and International Statistical Classification of Diseases and Related Health Problems, 10th revision, Australian Modification [ICD-10-AM] codes M05-M06) in the Hospital Morbidity Data Collection (HDMC) in Western Australia (WA) between 1985 and 2015, as well as nonexposed hospitalized controls matched on sex, age, and year of index admission. HDMC data were linked to the WA Cancer Registry and the WA Death Registry data, and cancer incidence rates (CIRs) per 1000 person-years, incidence rate ratios (IRR) with 95% CIs, and Kaplan Meier survival were estimated. Among 14,041 patients with RA (67.56% female, median age 65.1 years) and 33,785 controls (65.16% female, median age 65.3 years), preexisting cancer in patients with RA was less prevalent than in controls (7.6% vs 14.2%; P < 0.01). In participants without prior cancer, the overall post index CIR was lower in those with RA (CIR 19.68 vs 24.77; IRR 0.79, 95% CI 0.76-0.83) and stable over 3 study decades. CIR was higher in patients with RA for lung (CIR 1.17, 95% CI 1.04-1.34) and hematological cancer (CIR 1.21, 95% CI 1.03-1.43) but lower for most other cancer types. Overall median survival was lower for patients with RA than controls (3.3 vs 5.3 years; P < 0.001) with increased mortality rates observed for most cancer subtypes. Overall CIR in patients with RA was consistently lower over time than in matched controls. CIR was only increased for lung and hematological cancer. Despite the overall lower CIR, post cancer mortality was higher for patients with RA in most cancer subtypes.

In Silico Optimization of a Streptomyces sp. Antimicrobial Peptide Against Oncobacteria in Oral Squamous Cell Carcinoma

ABSTRACTOral squamous cell carcinoma (OSCC) is a major public health concern, accounting for more than 90% of all oral malignancies. Pathogenic bacteria, such as Streptococcus mutans, Fusobacterium nucleatum, and Porphyromonas gingivalis, are closely linked to OSCC and promote chronic inflammation, a key factor in the tumor microenvironment. The increasing incidence of oral malignancies necessitates the development of antimicrobial peptides (AMPs) with enhanced anticancer activity as targeted therapeutics against bacteria to mitigate their impact on OSCC. A total of 182 Streptomyces genus‐derived AMPs were collected and analyzed in silico to determine their potent antibacterial and anticancer characteristics. Fourteen AMPs were tested for 3D structural alignment prediction and validation, and the most efficient peptide was determined to be sAMP2. A genome‐based analysis of the peptide sourced from Streptomyces globisporus C‐1027 was conducted to explore its evolutionary significance. The cell‐penetrating peptide activity of sAMP2 was optimized to make it more stable and better able to target OSCC host cellular receptors. The peptide Mut_sAMP2 was found to interact with the bacterial virulence proteins DEX of S. mutans, LPS of F. nucleatum, and KGP of P. gingivalis and with OSCC‐associated proteins (TNFα, IL‐6, IL‐8, p38, p53, E‐cadherin, Jak‐1, and PAR2) with greater binding affinity. The peptide Mut_sAMP2 treated OECM‐1 cells showed reduced cell survival by the cytotoxicity activity of IC50 5.4 μg/mL. To the best of our knowledge, our computational study is the first to significantly impact the development of new and effective cancer therapeutics from Streptomyces sp. derived AMPs with a broad spectrum of activity and potential evaluating to combat OSCC progression linked with oral oncobacteria.

The Distribution and Predictive Factor of Extra-Pancreatic Malignancy Occurrence in Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm-A Ten-Year Follow-Up Case-Control Study in Taiwan.

A higher incidence of extra-pancreatic malignancies (EPMs) in patients with pancreatic intraductal papillary mucinous neoplasm (IPMN) than in the general population has been shown in several studies. We suppose that EPMs also occur after IPMN has been diagnosed, but few reports have discussed the risk factors that have been identified, except for old age, which was only noted in one study. Our study aims to recognize the distribution of EPMs in Taiwanese patients with a longer duration of follow-up and investigate the risk factors to predict EPMs in IPMN patients. We retrospectively analyzed 114 patients with pancreatic IPMN from 1 January 2010 to 31 December 2014 in Chang Gung Memorial Hospital. The characteristics of the patients were all recorded. Different EPMs are demonstrated as occurring before, concurrently with, or after IPMN diagnosis. The risk factors were compared between patients with or without an EPM. After an average follow-up duration of 10.45 years, 47 EPMs occurred in 42 patients (36.8%), and over half were found after IPMN was diagnosed (55.3%). The most common EPMs were colon cancer and lung cancer (21.3%). Moreover, cyst size progression was highly associated with EPM occurrence (p = 0.004) and predictive of EPM occurrence after IPMN (p = 0.002), with a cut-off value of 1 cm (accuracy: 79%; sensitivity: 88%; specificity: 58%). Colon cancer and lung cancer account for the majority EPMs in Taiwan. EPMs were also frequently found after IPMN diagnosis when the follow-up duration was prolonged up to 10.45 years. Cyst size progression is a risk factor of EPM after IPMN diagnosis and we suggest a cut-off value of 1 cm for clinical utility.